Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas
Claudia Curcio, … , Piero Musiani, Guido Forni
Claudia Curcio, … , Piero Musiani, Guido Forni
Published April 15, 2003
Citation Information: J Clin Invest. 2003;111(8):1161-1170. https://doi.org/10.1172/JCI17426.
View: Text | PDF
Article

Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas

  • Text
  • PDF
Abstract

Since the mechanisms by which specific immunity destroys Her-2/neu carcinoma cells are highly undetermined, these were assessed in BALB/c mice vaccinated with plasmids encoding extracellular and transmembrane domains of the protein product (p185neu) of the rat Her-2/neu oncogene shot into the skin by gene gun. Vaccinated mice rejected a lethal challenge of TUBO carcinoma cells expressing p185neu. Depletion of CD4 T cells during immunization abolished the protection, while depletion of CD8 cells during the effector phase halved it, and depletion of polymorphonuclear granulocytes abolished all protection. By contrast, Ig μ-chain gene KO mice, as well as Fcγ receptor I/III, β-2 microglobulin, CD1, monocyte chemoattractant protein 1 (MCP1), IFN-γ, and perforin gene KO mice were protected. Only mice with both IFN-γ and perforin gene KOs were not protected. Although immunization also cured all BALB/c mice bearing established TUBO carcinomas, it did not cure any of the perforin KO or perforin and IFN-γ KO mice. Few mice were cured that had knockouts of the gene for Ig μ-chain, Fcγ receptor I/III, IFN-γ, or β-2 microglobulin. Moreover, vaccination cured half of the CD1 and the majority of the MCP1 KO mice. The eradication of established p185neu carcinomas involves distinct mechanisms, each endowed with a different curative potential.

Authors

Claudia Curcio, Emma Di Carlo, Raphael Clynes, Mark J. Smyth, Katia Boggio, Elena Quaglino, Michela Spadaro, Mario P. Colombo, Augusto Amici, Pier-Luigi Lollini, Piero Musiani, Guido Forni

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Mechanism of r-p185 carcinoma eradication. When the tumor was 2 mm in di...
Mechanism of r-p185 carcinoma eradication. When the tumor was 2 mm in diameter, various KO mice were shot with p185 plasmid. Although all WT BALB/c mice were cured (20 of 20 cured at day 200) (Figure 2a), vaccination did not cure any BALB-pfpKO mice (0 of 7 cured, P < 0.0001 versus WT BALB/c) (f) or BALB-IFNγ-pfpKO mice (0 of 7 cured, P < 0.0001) (c). Vaccination did not cure 89% of BALB-μIgKO mice (2 of 18 cured, P < 0.0001) (a), 88% of BALB-FcγRI/IIIKO mice (1 of 8 cured, P < 0.001) (b), 86% of BALB-IFNγKO mice (3 of 21 cured, P < 0.0001) (e), and 78% of BALB-β2mKO mice (2 of 9 cured, P < 0.001) (g). Vaccination cured 54% of BALB-CD1KO mice (6 of 11 cured, P < 0.006) (h) and 80% of BALB-MCP1KO mice (12 of 15 cured, P < 0.07) (d). Arrows show the days of the shots, and the gray area shows the growth and the rejection of the tumor in WT BALB/c mice bearing 2-mm tumors.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts